Joint development and European registration of an injectable medical device containing NeoSilk human type I collagen
First written in FY2021-Q1. 1 of 2 entries say "Advanced", first in FY2024. Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024AdvancedAnnual report
「For the cosmetic ingredient NeoSilk®-human-type collagen I, the company also signed an OEM agreement with Italian company 303 Pharma, which has successfully developed beauty equipment and other products, and will provide the ingredient as a product under 303 Pharma's own brand.」
An OEM agreement was signed with 303 Pharma on 1 December 2023, advancing NeoSilk-human-type collagen I to the stage of being provided as a product under the company's own brand. - FY2021-Q1First statedAnnual report
「Giuliani S.p.A., a long-established Italian pharmaceutical company founded in 1889, jointly developed with Italian pharmaceutical venture 303 Pharma S.R.L. an injectable medical device containing the NeoSilk-human-type collagen I developed by the company, and completed its registration as a Class 3 device under 93/42/EEC/CE certification. The product is scheduled to be manufactured and sold by Giuliani S.p.A.」
The company described for the first time the expansion of NeoSilk-human-type collagen I beyond cosmetics into injectable medical devices. The disclosure indicated that Giuliani S.p.A. and 303 Pharma S.R.L. jointly developed the product, completed its registration as a Class 3 device, and that Giuliani S.p.A. is scheduled to manufacture and sell it.